| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Chief Accounting Officer | SVP, Chief Accounting Officer | VP, Corp Controller And CAO
1 company
Calvin Sandra is a SVP, Chief Accounting Officer at Travere Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 12 sells.
Estimated insider holdings value: $2.2M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 910 | $9.07 | $8,252.24 | -2.2% | -37.0% | +109.5% | |
| May 11, 2023 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 558 | $16.49 | $9,199.88 | -0.7% | -5.6% | -61.0% | |
| Feb 2, 2023 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 2,031 | $21.87 | $44,418.79 | -2.3% | -29.4% | -62.4% | |
| Jan 25, 2023 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 1,097 | $21.86 | $23,976.44 | -1.5% | -1.9% | -57.2% | |
| Sep 13, 2022 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 349 | $28.00 | $9,772.00 | -1.0% | -28.8% | -48.8% | |
| May 11, 2022 | TVTX Travere Therapeutics, Inc. | SVP, Chief Accounting Officer | Sell | 881 | $21.72 | $19,134.32 | -1.2% | +30.5% | -24.4% | |
| Jan 31, 2022 | TVTX Travere Therapeutics, Inc. | VP, Corp Controller And CAO | Sell | 798 | $26.51 | $21,151.71 | -2.1% | -6.4% | -18.5% | |
| Jan 24, 2022 | TVTX Travere Therapeutics, Inc. | VP, Corp Controller And CAO | Sell | 934 | $24.58 | $22,954.64 | -3.2% | +9.9% | -16.2% |